1-5 of 5
J. Alejandro Perez-Fidalgo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Komal L. Jhaveri, Meritxell Bellet, Nicholas C. Turner, Sherene Loi, Aditya Bardia, Valentina Boni, Joohyuk Sohn, Tomas G. Neilan, Rafael Villanueva-Vázquez, Peter Kabos, Laura García-Estévez, Elena López-Miranda, J. Alejandro Pérez-Fidalgo, Jose M. Pérez-García, Jiajie Yu, Jill Fredrickson, Heather M. Moore, Ching-Wei Chang, John W. Bond, Jennifer Eng-Wong, Mary R. Gates, Elgene Lim
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 754–766.
https://doi.org/10.1158/1078-0432.CCR-23-1796
Published: 16 February 2024
View article titled, Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
Open the PDF for Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Ingrid A. Mayer, Aleix Prat, Daniel Egle, Sibel Blau, J. Alejandro Pérez Fidalgo, Michael Gnant, Peter A. Fasching, Marco Colleoni, Antonio C. Wolff, Eric P. Winer, Christian F. Singer, Sara Hurvitz, Laura García Estévez, Peter A. van Dam, Sherko Kümmel, Christoph Mundhenke, Frankie Holmes, Naveen Babbar, Laure Charbonnier, Ivan Diaz-Padilla, Florian D. Vogl, Dalila Sellami, Carlos L. Arteaga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (10): 2975–2987.
https://doi.org/10.1158/1078-0432.CCR-18-3160
Published: 15 May 2019
View article titled, A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Open the PDF for A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB) in another window
Includes: Supplementary data
Journal Articles

Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung-Min Lee, Luis J. Schwarz, Jennifer M. Giltnane, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín Gavilá, J. Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mónica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1431.
https://doi.org/10.1158/1078-0432.CCR-18-4270
Published: 15 February 2019
View article titled, Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Open the PDF for Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors in another window
Journal Articles

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung-Min Lee, Luis J. Schwarz, Jennifer M. Giltnane, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín Gavilá, J. Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mónica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (11): 2517–2529.
https://doi.org/10.1158/1078-0432.CCR-17-2904
Published: 31 May 2018
View article titled, ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Open the PDF for ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors in another window
Includes: Supplementary data
Journal Articles

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Udai Banerji, Emma J. Dean, J. Alejandro Pérez-Fidalgo, Gerald Batist, Philippe L. Bedard, Benoit You, Shannon N. Westin, Peter Kabos, Michelle D. Garrett, Mathew Tall, Helen Ambrose, J. Carl Barrett, T. Hedley Carr, S.Y. Amy Cheung, Claire Corcoran, Marie Cullberg, Barry R. Davies, Elza C. de Bruin, Paul Elvin, Andrew Foxley, Peter Lawrence, Justin P.O. Lindemann, Rhiannon Maudsley, Martin Pass, Vicky Rowlands, Paul Rugman, Gaia Schiavon, James Yates, Jan H.M. Schellens
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (9): 2050–2059.
https://doi.org/10.1158/1078-0432.CCR-17-2260
Published: 30 April 2018
View article titled, A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <em>PIK3CA</em>-Mutated Breast and Gynecologic Cancers
Open the PDF for A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <em>PIK3CA</em>-Mutated Breast and Gynecologic Cancers in another window
Includes: Supplementary data